Table 1 Characteristic of included studies
Author | Year | Country | Subjects | R/S | Gene | TP (n) | FP (n) | FN (n) | TN (n) | NOS | Refs. |
|---|---|---|---|---|---|---|---|---|---|---|---|
Pietzka | 2009 | Austria | Multidrug-resistant TB | 49/19 | rpoB | 44 | 2 | 5 | 17 | 8 | [18] |
Choi | 2010 | Korea | Isoniazid resistance Rifampicin resistance | 100/117 73/124 | katG, inhA rpoB | 90 72 | 0 0 | 10 1 | 117 124 | 10 | [19] |
Ong | 2010 | Singapore | Isoniazid resistance Rifampicin resistance | 53/6 28/31 | katG and mab-inhA rpoB | 52 25 | 1 0 | 1 3 | 5 31 | 8 | [20] |
Ramirez | 2010 | United States | Multidrug-resistant TB | 148/104 | katG, inhA rpoB | 126 | 2 | 22 | 102 | 8 | [21] |
Wang | 2011 | China | Streptomycin resistance | 30/0 | rpsL | 21 | 0 | 9 | 0 | 5 | [22] |
Chen | 2011 | Australia | Isoniazid resistance Rifampicin resistance Ofloxacin resistance | 69/46 54/61 41/74 | katG and mab-inhA rpoB gyrA | 67 51 41 | 0 1 1 | 2 3 0 | 48 60 73 | 9 | [23] |
Lee | 2012 | Singapore | Fluoroquinolone and Streptomycin resistance | 25/28 48/14 | gyrA rpsL | 19 42 | 0 0 | 6 6 | 28 14 | 7 | [24] |
Yadav | 2012 | India | Isoniazid resistance Rifampicin resistance Streptomycin resistance | 35/20 29/20 34/20 | katG rpoB rpsL | 30 27 21 | 2 0 0 | 5 2 13 | 18 20 20 | 9 | [25] |
Nagai | 2013 | Japan | Isoniazid resistance Rifampicin resistance Ethambutol resistance Streptomycin resistance | 12/15 10/17 8/19 11/16 | katG, mab-inhA rpoB embB rpsL, rrs | 11 10 8 11 | 0 2 0 1 | 1 0 0 0 | 15 15 19 15 | 10 | [26] |
Nour | 2013 | Egypt | Isoniazid resistance Rifampicin resistance | 20/10 13/17 | katG, rpoB | 17 12 | 0 0 | 3 1 | 10 17 | 6 | [27] |
Haeili | 2014 | Iran | Isoniazid resistance Rifampicin resistance | 21/54 20/54 | katG rpoB | 18 19 | 0 0 | 3 1 | 54 54 | 8 | [28] |
Pholwat | 2014 | United States | Pyrazinamide resistance | 55/41 | pncA | 34 | 7 | 21 | 34 | 8 | [29] |
Malhotra | 2015 | India | Rifampicin resistance | 103/116 | rpoB | 93 | 3 | 10 | 113 | 9 | [30] |
Pholwat | 2015 | United states | Drug-resistant TB | 186/41 161/58 80/123 107/304 40/180 56/57 | inhA or katG rpoB embB rpsL, rrs, eis gyrA-gyrB pncA | 174 153 62 89 31 49 | 0 11 35 18 3 2 | 12 8 18 18 9 7 | 41 47 88 286 177 55 | 10 | [31] |
Osman | 2016 | Africa | Pyrazinamide resistance | 29/66 | pncA | 14 | 17 | 15 | 49 | 7 | [32] |
Galarza | 2016 | Peru | Multidrug-resistant TB Isoniazid resistance Rifampicin resistance | 78/89 78/89 78/89 | katG, inhA rpoB | 77 77 77 | 2 2 0 | 1 1 1 | 87 87 89 | 8 | [33] |
Anthwal | 2017 | India | Isoniazid resistance Rifampicin resistance | 21/78 11/88 | katG, inhA rpoB | 18 10 | 0 0 | 3 1 | 88 88 | 9 | [34] |
Rezaei | 2017 | Iran | Ethambutol resistance Streptomycin resistance | 21/55 25/51 | embB rrs, rpsL | 19 22 | 2 0 | 2 3 | 53 51 | 6 | [35] |
Sirous | 2018 | Iran | Isoniazid resistance Rifampicin resistance Ofloxacin resistance | 16/20 18/20 5/20 | katG and mab-inhA rpoB gyrA | 14 15 4 | 0 0 0 | 2 3 1 | 20 20 20 | 10 | [36] |
Negi | 2018 | India | Multidrug-resistant TB | 94/49 | katG, rpoB | 85 | 0 | 9 | 49 | 8 | [37] |
Filipenko | 2019 | Russia | Pyrazinamide resistance | 38/20 | pncA | 31 | 3 | 7 | 17 | 7 | [38] |
Arefzadeh | 2020 | Iran | Rifampicin resistance | 5/75 | rpoB | 5 | 8 | 0 | 67 | 8 | [39] |
Anukool | 2020 | Thailand | Isoniazid resistance Rifampicin resistance | 34/69 37/70 | katG, inhA rpoB | 33 31 | 4 1 | 1 6 | 65 69 | 9 | [40] |
Wang | 2020 | China | Ethambutol resistance | 59/163 | embB | 49 | 9 | 10 | 154 | 7 | [41] |